BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12855655)

  • 1. Proliferation of CD30+ T-helper 2 lymphoma cells can be inhibited by CD30 receptor cross-linking with recombinant CD30 ligand.
    Willers J; Dummer R; Kempf W; Kündig T; Burg G; Kadin ME
    Clin Cancer Res; 2003 Jul; 9(7):2744-54. PubMed ID: 12855655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
    Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
    Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
    Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
    J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of murine B cell growth and differentiation by CD30 ligand.
    Shanebeck KD; Maliszewski CR; Kennedy MK; Picha KS; Smith CA; Goodwin RG; Grabstein KH
    Eur J Immunol; 1995 Aug; 25(8):2147-53. PubMed ID: 7664777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response.
    Pellegrini P; Berghella AM; Contasta I; Adorno D
    Transpl Immunol; 2003; 12(1):49-61. PubMed ID: 14551032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reverse signaling via CD30 ligand.
    Wiley SR; Goodwin RG; Smith CA
    J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
    Hsu PL; Hsu SM
    Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD30 ligand in lymphoma patients with CD30+ tumors.
    Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
    J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of CD30 and CD30 ligand in cultured cell lines from human germ-cell tumors.
    Pera MF; Bennett W; Cerretti DP
    Lab Invest; 1997 Apr; 76(4):497-504. PubMed ID: 9111512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice.
    Sun X; Somada S; Shibata K; Muta H; Yamada H; Yoshihara H; Honda K; Nakamura K; Takayanagi R; Tani K; Podack ER; Yoshikai Y
    Gastroenterology; 2008 Feb; 134(2):447-58. PubMed ID: 18242212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299.
    Hübinger G; Müller E; Scheffrahn I; Schneider C; Hildt E; Singer BB; Sigg I; Graf J; Bergmann L
    Oncogene; 2001 Feb; 20(5):590-8. PubMed ID: 11313991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
    Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
    Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
    Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
    Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of CD30 ligand and interleukin 4 (IL-4) receptors by acute myeloid leukaemia blasts is associated with the expansion of IL-4-producing CD30+ normal T cells.
    Rossi FM; Degan M; Mazzocco FT; Di Francia R; Aldinucci D; Poletto D; Vellenga E; Pinto A; Gattei V
    Br J Haematol; 2002 Apr; 117(1):59-69. PubMed ID: 11918534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
    Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
    Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
    Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
    Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
    Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
    Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1).
    Pfeifer W; Levi E; Petrogiannis-Haliotis T; Lehmann L; Wang Z; Kadin ME
    Am J Pathol; 1999 Oct; 155(4):1353-9. PubMed ID: 10514417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
    Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
    Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression.
    Levi E; Wang Z; Petrogiannis-Haliotis T; Pfeifer WM; Kempf W; Drews R; Kadin ME
    J Invest Dermatol; 2000 Dec; 115(6):1034-40. PubMed ID: 11121138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.